



Stabilis



Epinephrine hydrochloride



Noms commerciaux

Adrenalin	Allemagne, Canada, Danemark, Espagne, Finlande, Islande, Luxembourg, Norvège, Suède, Suisse, Turquie
Adrenalina	Argentine, Colombie, Espagne, Portugal, Roumanie
Adrenaline	Arabie Saoudite, Egypte, France, Nouvelle Zélande
Anapen	Allemagne, Autriche, France, Grande Bretagne, Pays bas, Suède, Suisse
Emerade	Allemagne, Roumanie
Epipen	Argentine, Autriche, Belgique, Canada, Danemark, Etats Unis d'Amérique, Finlande, Grande Bretagne, Norvège, Nouvelle Zélande, Pays bas, Suède, Suisse
L - Adrenalin	Autriche
Levophed	Grèce
Levopress	Vénézuela
Min I Ject Adrenalin	Grande Bretagne
Pinadrina	Mexique
Suprarenin	Allemagne, Autriche
Tonogen	Hongrie
Vasocon	Inde



Stabilité des solutions

		100 µg/ml	25°C		7			659
		100 µg/ml	25°C		7			659
		700 µg/ml	25°C		56			659
		700 µg/ml	25°C		56			659
		16 µg/ml	23-25°C		45			4026
		16 µg/ml	3-5°C		60			4026
		64 µg/ml	23-25°C		45			4026

		64 µg/ml	3-5°C		60				4026
		100 µg/ml	23°C		24				192
		16 µg/ml	5°C		20				197
		100 µg/ml	25°C		7				659
		700 µg/ml	25°C		56				659
		20 µg/ml	23°C		84				3712
		300 µg/ml	23°C		84				3712
		900 µg/ml	23°C		84				3712
		10 µg/ml	2-8°C		90				4323
		10 µg/ml	20-25°C		12				4778
		10 µg/ml	25°C		21				4393
		10 µg/ml	4°C		56				4393
		10 µg/ml	4°C		56				4778
		20 µg/ml	2-8°C		183				3445
		20 µg/ml	2-8°C		180				3397
		20 µg/ml	23°C		84				3712
		300 µg/ml	23°C		84				3712
		900 µg/ml	23°C		84				3712
		100 µg/ml	2-8°C		172				3309
		100 µg/ml	25°C		30				3704
		100 µg/ml	4°C		30				3704
		25 µg/ml	25°C		30				3704
		25 µg/ml	4°C		30				3704
		50 µg/ml	25°C		30				3704
		50 µg/ml	4°C		30				3704



Stabilité en mélange

		2 & 100 µg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4		1603
		0,1 µg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		0,03 µg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
	RL	0,1 µg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280

		0,1 µg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
PVC		0,0006 µg/ml	30°C		Bupivacaine hydrochloride : 0,43 mg/ml Fentanyl citrate : 1,25 µg/ml	48		217
PVC		0,0006 µg/ml	3°C		Bupivacaine hydrochloride : 0,43 mg/ml Fentanyl citrate : 1,25 µg/ml	20		217
PVC		2 µg/ml	18-22°C		Fentanyl citrate : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml	184		2306
PVC		2 µg/ml	4°C		Bupivacaine hydrochloride : 1 mg/ml Fentanyl citrate : 2 µg/ml	184		2306
PP		3,5 µg/ml	22°C		Lidocaine hydrochloride : 3,5 mg/ml Bleomycin sulfate : 0,75 mg/ml	1		3420
PP		3,5 µg/ml	4°C		Lidocaine hydrochloride : 3,5 mg/ml Bleomycin sulfate : 0,75 mg/ml	3		3420
PP		2 µg/ml	22°C		Fentanyl citrate : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml	180		1875
PP		9 µg/ml	4-7°C		Lidocaine hydrochloride : 9 mg/ml Sodium bicarbonate : 7,8 mg/ml	7		2878
PP		9 µg/ml	4-7°C		Lidocaine hydrochloride : 18 mg/ml Sodium bicarbonate : 7,8 mg/ml	7		2878
PP		2 µg/ml	4°C		Fentanyl citrate : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml	180		1875
		32 µg/ml	25°C		Calcium chloride : 4 mg/ml	26		3622
		2 µg/ml	20-24°C		Fentanyl citrate : 4,1 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml	40		3401
		2 µg/ml	20-24°C		Fentanyl citrate : 4,1 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml	48		3401
		2 µg/ml	4-8°C		Fentanyl citrate : 4,1 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml	60		3401








Facteur influençant la stabilité

				1965 2089
				3401
				197
				3642
				2306
	PH >7			3642
	PH > 6			197





























Compatibilités

				
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 16>>>32 µg/ml	Normo Sol®	4655
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 1000 µg/ml	RL	4603
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 0,2 µg/ml Alprostadil : 20 µg/ml	◆	4491
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 200 µg/ml Alprostadil : 20 µg/ml	◆	4651
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 1000 µg/ml Amiodarone hydrochloride : 6 mg/ml	◆	1611
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 1000 µg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 50 µg/ml Anidulafungin : 0.5 mg/ml	◆	1982
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 4 µg/ml Atracurium besylate : 0.5 mg/ml	◆	402
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 100 µg/ml Caffeine : 10 mg/ml	∅	3964
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 0,05 µg/ml Caspofungin acetate : 0,7 mg/ml	▲	2247
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 16 µg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲◆	4528
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 100 µg/ml Cefpirome sulfate : 50 mg/ml	▲◆	280
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 50 µg/ml Ceftazidime : 125 mg/ml	💧	2141
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 16 µg/ml Ceftolozane / tazobactam : 10/5 mg/ml	▲◆	3828
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 0.1 µg/ml Cimetidine hydrochloride : 3 mg/ml	◆	1201
	<input type="checkbox"/>	Epinephrine hydrochloride : 1 & 10 µg/ml	NaH CO ₃	2077
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 50 µg/ml Bivalirudin : 5 mg/ml	◆	1713
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 32 µg/ml Calcium chloride : 4 mg/ml	▲	3622
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 0.032 µg/ml Calcium chloride : 20 mg/ml	◆	4732
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 0.064 µg/ml Calcium chloride : 20 mg/ml	◆	4732
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 100 µg/ml Cefpirome sulfate : 50 mg/ml	▲ 0.43	280
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 50 µg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	◆	299
	<input type="checkbox"/>	Epinephrine hydrochloride	NaH CO ₃	3642
<input checked="" type="checkbox"/>		Epinephrine hydrochloride : 100 µg/ml Cefpirome sulfate : 50 mg/ml	RL	280

	Epinephrine hydrochloride : 20 µg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
	Epinephrine hydrochloride : 9.6 µg/ml		3379
	Epinephrine hydrochloride : 200 µg/ml		939
	Epinephrine hydrochloride : 100 µg/ml Cloxacillin sodium : 100 mg/ml		3012
	Epinephrine hydrochloride : 1000 µg/ml Cloxacillin sodium : 100 mg/ml		3012
	Epinephrine hydrochloride : 50 µg/ml Dexmedetomidine : 4 µg/ml		1712
	Epinephrine hydrochloride : 1000 µg/ml Diatrizoate meglumine : 283 mg/ml		1085
	Epinephrine hydrochloride : 20 µg/ml Diltiazem hydrochloride : 1 mg/ml		314
	Epinephrine hydrochloride : 4 µg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Epinephrine hydrochloride : 50 µg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Epinephrine hydrochloride : 0.1 µg/ml Dobutamine hydrochloride : 2 mg/ml		1041
	Epinephrine hydrochloride : 20 µg/ml Dobutamine hydrochloride : 4 mg/ml		314
	Epinephrine hydrochloride : 20 µg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Epinephrine hydrochloride : 16 µg/ml Eravacycline : 0,6 mg/ml		4434
	Epinephrine hydrochloride : 128 µg/ml Esmolol hydrochloride : 10 mg/ml		3879
	Epinephrine hydrochloride : 40 µg/ml Esomeprazole sodium : 0.32 mg/ml		1506
	Epinephrine hydrochloride : 4 µg/ml Famotidine : 0.2 mg/ml		398
	Epinephrine hydrochloride : 50 µg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Epinephrine hydrochloride : 20 µg/ml Fentanyl citrate : 50 µg/ml		314
	Epinephrine hydrochloride : 8 µg/ml Flucloxacillin sodium : 20 mg/ml		1232
	Epinephrine hydrochloride : 16 µg/ml Fosfomycin : 30 mg/ml		4055
	Epinephrine hydrochloride : 16 & 100 µg/ml Furosemide : 10 mg/ml		4570
	Epinephrine hydrochloride : 20 µg/ml Furosemide : 10 mg/ml		314
	Epinephrine hydrochloride : 200 µg/ml Furosemide : 10 mg/ml		3210
	Epinephrine hydrochloride : 8 µg/ml Furosemide : 1 mg/ml		1232
	Epinephrine hydrochloride : 16 & 100 µg/ml Furosemide : 1 mg/ml		4570
	Epinephrine hydrochloride : 20 µg/ml Heparin sodium : 100 UI/ml		314

	Epinephrine hydrochloride : 100 µg/ml Heparin sodium : 1 UI/ml		1228
	Epinephrine hydrochloride : 100 µg/ml Heparin sodium : 1 UI/ml	RL	1228
	Epinephrine hydrochloride : 50 µg/ml Hetastarch : 60 mg/ml		1721
	Epinephrine hydrochloride Hyaluronidase		3617
	Epinephrine hydrochloride Hyaluronidase		3184
	Epinephrine hydrochloride : 100 µg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
	Epinephrine hydrochloride : 128 µg/ml Hydrocortisone sodium succinate : 1 mg/ml		4465
	Epinephrine hydrochloride : 100 µg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
	Epinephrine hydrochloride : 20 µg/ml Hydromorphone hydrochloride : 1 mg/ml		314
	Epinephrine hydrochloride Hydroxocobalamin		3932
	Epinephrine hydrochloride : 8 >> 100 µg/ml Ibuprofen lysinate : 10 mg/ml		4419
	Epinephrine hydrochloride : 50 µg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Epinephrine hydrochloride : 60 & 300 µg/ml Insulin aspart : 1 UI/ml		1508
	Epinephrine hydrochloride : 1000 µg/ml Iohexol : 300 mg I/ml	∅	1085
	Epinephrine hydrochloride : 1000 µg/ml Ioxaglate : 320 mg I/ml	∅	1085
	Epinephrine hydrochloride Iron (polymaltose)		3642
	Epinephrine hydrochloride Iron dextran		3642
	Epinephrine hydrochloride : 16 µg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Epinephrine hydrochloride : 1000 µg/ml Ketamine hydrochloride : 50 mg/ml		2109
	Epinephrine hydrochloride : 128 µg/ml Labetalol hydrochloride : 5 mg/ml		3879
	Epinephrine hydrochloride : 20 µg/ml Labetalol hydrochloride : 2 mg/ml		314
	Epinephrine hydrochloride : 1000 µg/ml Levofloxacin : 5 mg/ml		1072
	Epinephrine hydrochloride : 1000 µg/ml Levosimendan : 2,5 mg/ml		4389
	Epinephrine hydrochloride : 9 µg/ml Lidocaine hydrochloride : 9 & 18 mg/ml		2878
	Epinephrine hydrochloride : 20 µg/ml Lorazepam : 0.5 mg/ml		314
	Epinephrine hydrochloride : 1000 µg/ml Meropenem : 50 mg/ml		4319

		Epinephrine hydrochloride : 128 µg/ml Metoprolol tartrate : 0.4 mg/ml		3879
		Epinephrine hydrochloride : 50 µg/ml Micafungin : 1.5 mg/ml		2108
		Epinephrine hydrochloride : 20 µg/ml Midazolam hydrochloride : 2 mg/ml		314
		Epinephrine hydrochloride : 20 µg/ml Milrinone lactate : 0.2 mg/ml		314
		Epinephrine hydrochloride : 32 µg/ml Milrinone lactate : 1 mg/ml		4506
		Epinephrine hydrochloride : 128 µg/ml Milrinone lactate : 0.8 mg/ml		813
		Epinephrine hydrochloride : 20 µg/ml Morphine sulfate : 2 mg/ml		314
		Epinephrine hydrochloride : 1000 µg/ml N-acetylcysteine : 200 mg/ml		3766
		Epinephrine hydrochloride : 1000 µg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Epinephrine hydrochloride : 20 µg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Epinephrine hydrochloride : 20 µg/ml Nitroglycerin : 0.4 mg/ml		314
		Epinephrine hydrochloride : 20 µg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Epinephrine hydrochloride : 40 µg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Epinephrine hydrochloride : 4 µg/ml Pancuronium bromide : 0.05 mg/ml		402
		Epinephrine hydrochloride : 16 >> 32 µg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
		Epinephrine hydrochloride Pantoprazole sodium		2090
		Epinephrine hydrochloride : 1 µg/ml Paracetamol : 10 mg/ml		4742
		Epinephrine hydrochloride : 12 µg/ml Pentoxifyllin : 5 mg/ml		4543
		Epinephrine hydrochloride : 16 µg/ml Plazomicin sulfate : 24 mg/ml		4145
		Epinephrine hydrochloride : 100 µg/ml Potassium chloride : 40 mEq/l	 	1228
		Epinephrine hydrochloride : 100 µg/ml Potassium chloride : 40 mEq/l	RL	1228
		Epinephrine hydrochloride : 100 µg/ml Propofol : 10 mg/ml		300
		Epinephrine hydrochloride : 0.1 µg/ml Propofol		660
		Epinephrine hydrochloride : 20 µg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Epinephrine hydrochloride : 50 µg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Epinephrine hydrochloride : 1 & 10 µg/ml Sodium bicarbonate : 84 mg/ml		2077

		Epinephrine hydrochloride Sodium bicarbonate		3086
		Epinephrine hydrochloride : 1000 µg/ml Sugammadex : 100 mg/ml		3372
		Epinephrine hydrochloride : 0,016 µg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Epinephrine hydrochloride : 16 µg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Epinephrine hydrochloride : 50 µg/ml Temocilline : 83.33 mg/ml		2231
		Epinephrine hydrochloride : 20 µg/ml Thiopental sodium : 25 mg/ml		314
		Epinephrine hydrochloride : 2 & 100 µg/ml Tirofiban : 50 µg/ml		1603
		Epinephrine hydrochloride Tirofiban		1512
		Epinephrine hydrochloride : 50 µg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Epinephrine hydrochloride : 4 µg/ml Vasopressin : 2 & 4 UI/ml		1801
		Epinephrine hydrochloride : 20 µg/ml Vecuronium bromide : 1 mg/ml		314
		Epinephrine hydrochloride : 4 µg/ml Vecuronium bromide : 0.1 mg/ml		402
		Epinephrine hydrochloride : 2 µg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Epinephrine hydrochloride : 100 µg/ml Warfarin sodium : 0.1 & 2 mg/ml		552



Voie d'administration



Bibliographie

	Type	Source
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
192	Revue	Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1417-1419.
197	Revue	Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340.

198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
217	Revue	Allen LV, Stiles ML, Wang DP, Tu YH. Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs. Am J Hosp Pharm 1993 ; 50: 714-715.
280	Revue	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
552	Revue	Martinez JF, Trissel LA, Gilbert DL. Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions. Int J Pharm Compound 1997 ; 1: 356-358.
659	Revue	Donnelly RF, Yen M. Epinephrine stability in plastic syringes and glass vials. Can J Hosp Pharm 1996 ; 49: 62-65.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.

1085	Revue	Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1603	Revue	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1875	Revue	Kjonniksen I, Brustugun J, Breivik H, Anderssen E, Klem W. Stability of an epidural analgesic solution containing adrenaline, bupivacaine and fentanyl. Acta Anaesthesiol Scand 2000 ; 44: 864-867.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1965	Revue	Brustugun J, Kristensen S, Tonnesen HH. Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. PDA J Pharm Sci Technol 2004 ; 58, 6: 296-308.

1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2077	Revue	Bonhomme L, Benhamou D, Comoy E, Preaux N. Stability of epinephrine in alkalized solutions. Ann Emerg Med 1990 ; 19: 1242-1244.
2089	Revue	Brustugun J, Kristensen S, Tonnesen HH. Photostability of epinephrine - the influence of bisulfite and degradation products. Pharmazie 2004 ; 59: 457-463.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2306	Revue	Priston M.J, Hughes J.M, Santillo M, Christie I.W. Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine. Anaesthesia 2004 ; 59, 10: 979-983.
2878	Revue	Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 5: 375-380.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3086	Revue	Robinson, J, Fernando, R, Sun Wai, W.Y., Reynolds, F. Chemical stability of bupivacaine, lidocaine and epinephrine in pH-adjusted solutions. Anaesthesia 2000 ; 55, 9: 853-858.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005

3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3309	Revue	Zenoni D, Priori G, Bellan C, Invernizzi R.W. Stability of diluted epinephrine in prefilled syringes for use in neonatology. EJHP 2012 ;19:378-380
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3397	Poster	Heeb R.M, Krämer I. Physicochemical stability of ready-to-administer epinephrine injection solutions 20 µg/mL, 50 mL. EAHP Congress Paris 2013
3401	Revue	Helin-Tanninen, M., Lehtonen, M., Naaranlahti, T., Ven?inen, T., Pentik?inen, J., Laatikainen, A., Kokki, H. Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine. J Clin Pharm Ther 2013 ;38, 2: 104-108
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3420	Revue	El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P. Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology J Oncol Pharm Practice 2014 ; 21, 3: 178-187.
3445	Revue	Heeb R.M, Thiesen J, Krämer I. Aseptische Herstellung applikationsfertiger Adrenalin-Dauerinjektionen 20 µg/ml. Krankenhauspharmazie 2013 ; 34, 8: 410-411.
3617	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3622	Revue	Weeks Phillip A, Teng Yang, Wu Lei, Sun Mary, Yang Zhen, Chow Diana S-L. Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride. Int J Pharm Compound 2014 ; 18, 2 : 152-158.
3642	Laboratoire	Epinephrine - Résumé des Caractéristiques du Produit International Medication System (UK) 2013
3704	Revue	Carr R.R, Decarie D, Ensom M.H.H Stability of Epinephrine at Standard Concentrations Can J Hosp Pharm 2014 ; 67, 3:179-202.
3712	Revue	Ghanayem N.S, Lee L, Nelson T, Wong S, Gordon G.B, Markdante K et al. Stability of dopamine and epinephrine solutions up to 84 hours. Pediatr Crit Care Med 2001 ; 2, 4: 315-317.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98

3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Revue	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4026	Revue	Van Matre E.T, Ho K.C., Lyda C, Fullmer B.A, Oldlan A.R, Kiser T.H. Extended Stability of Epinephrine Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light-Blocking Bags. Hosp Pharm 2017 ; 52, 8 : 570-573
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4323	Poster	Wethmar U, Hochbrügge H, Strobel HG. Stabilitätsprüfung von applikationsfertigen Adrenalin- und Noradrenalinverdünnungen. ADKA Kongress 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévოსимendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4393	Poster	Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E. Chemical Stability of Epinephrine Diluted in 0.9% Sodium Chloride and Stored in Polypropylene (PP) Syringes at 4°C and 25°C. Sunnybrook Health Sciences Centre 2020
4419	Revue	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.

4465	Revue	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4491	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4506	Revue	Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4570	Revue	Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4651	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Revue	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4732	Revue	Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3:164–170
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4778	Revue	Hook R, Neault A, Scharer D, Law S, Walker S.E, Ma N.H, Riss V. Chemical stability of epinephrine 10 µg/mL diluted in 0.9% sodium chloride and stored in polypropylene syringes at 4°C and 25°C. Int J Pharm Compound 2023 ; 27, 4: 347-351.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	Sympathomimétique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Eau pour préparation injectable		A l'abri de la lumière
	Jour		Polyvinyl chlorure
	Chlorure de sodium 0,9%		Lumière
	Glucose 5%		Heure
	Seringue polypropylène		NaCl 0,9% ou glucose 5%
	Non précisée		Glucose 10%
	Seringue polycarbonate		Non précisé
	Stabilité en mélange		Solvant
	Molécule	RL	Ringer lactate
	Chlorure de sodium 0,45%		Non précisé
	Polypropylène		Aucun
	Avec ou sans lumière		Facteur influençant la stabilité
	Provoque		Dégradation
	Augmentation stabilité		NaHCO ₃
	Augmentation		Compatibilités
	Compatible		Normosol®
	Instabilité chimique		Incompatible
	Incompatibilité non précisée		Nutrition parentérale (mélange binaire)
	Solvant spécifique		Précipitation en 4 heures
	Précipitation immédiate		Instabilité de l'émulsion à 6 heures
	Changement de couleur à 4 heures		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Intramusculaire		Sous cutanée



Intracardiaque



Bibliographie



Dictionnaire